| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
82,823,000 |
| Market
Cap: |
1.67(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$18.92 - $29.92 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 484 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Veracyte is a genomic diagnostics company. Co. develops tests that address clinical needs in the diagnosis, prognosis and treatment of cancer and other diseases. Co. provides tests in: thyroid cancer via its Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas; prostate cancer via its Decipher Biopsy and Radical Prostatectomy Genomic Classifiers; breast cancer via its Prosigna Breast Cancer Assay; lung cancer via its Percepta GSC and Percepta Nasal Swab Test; interstitial lung diseases including idiopathic pulmonary fibrosis via its Envisia Genomic Classifier; bladder cancer via its Decipher Bladder Genomic Classifier; and colon cancer via its Immunoscore Colon Cancer Test.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
60,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$980,094 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
20,000 |
20,000 |
104,169 |
535,146 |
| Total Sell Value |
$460,127 |
$460,127 |
$2,968,197 |
$14,025,264 |
| Total People Sold |
2 |
2 |
4 |
8 |
| Total Sell Transactions |
2 |
2 |
12 |
30 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Eastham Karin |
Director |
– • – |
2021-08-02 |
4 |
AS |
$43.54 |
$193,194 |
I/I |
(4,400) |
4,400 |
|
-10% |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2021-06-23 |
4 |
AS |
$39.75 |
$173,914 |
D/D |
(4,375) |
51,887 |
|
23% |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2021-06-23 |
4 |
OE |
$24.69 |
$108,019 |
D/D |
4,375 |
56,262 |
|
- |
|
| Bishop John L |
Director |
– • – |
2021-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
8,720 |
8,720 |
|
- |
|
| Jones Evan/ Fa |
Director |
– • – |
2021-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
8,720 |
38,720 |
|
- |
|
| Gordon Kevin K |
Director |
– • – |
2021-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
8,720 |
8,720 |
|
- |
|
| Epstein Robert S |
Director |
– • – |
2021-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
8,720 |
8,720 |
|
- |
|
| Eastham Karin |
Director |
– • – |
2021-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
8,720 |
8,720 |
|
- |
|
| Holstein Jens |
Director |
– • – |
2021-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
8,720 |
10,720 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2021-06-04 |
4 |
AS |
$33.28 |
$314,515 |
D/D |
(9,081) |
51,887 |
|
31% |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2021-06-04 |
4 |
OE |
$5.98 |
$102,135 |
D/D |
8,156 |
60,968 |
|
- |
|
| Holstein Jens |
Director |
– • – |
2021-06-03 |
4 |
B |
$35.19 |
$70,389 |
D/D |
2,000 |
2,000 |
2.39 |
23% |
|
| Anderson Bonnie H |
Executive Chairwoman |
• • – |
2021-06-02 |
4 |
D |
$36.07 |
$82,528 |
D/D |
(2,288) |
189,725 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2021-06-02 |
4 |
D |
$36.07 |
$32,896 |
D/D |
(912) |
52,812 |
|
- |
|
| Stapley Marc |
Chief Executive Officer |
• – – |
2021-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
46,807 |
46,807 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2021-05-17 |
4 |
OE |
$5.61 |
$78,905 |
D/D |
14,065 |
192,013 |
|
- |
|
| Alley Beverly Jane |
VP, Corporate Controller |
• – – |
2021-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
5,500 |
13,000 |
|
- |
|
| Eastham Karin |
Director |
– • – |
2021-05-03 |
4 |
AS |
$48.01 |
$213,700 |
I/I |
(4,427) |
8,800 |
|
6% |
|
| Bhanji Muna |
Director |
– • – |
2021-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
11,541 |
11,541 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2021-03-04 |
4 |
AS |
$47.11 |
$2,567,271 |
D/D |
(52,015) |
53,724 |
|
-24% |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2021-03-04 |
4 |
OE |
$5.98 |
$582,299 |
D/D |
30,970 |
105,739 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2021-03-02 |
4 |
D |
$62.15 |
$372,589 |
D/D |
(5,995) |
74,769 |
|
- |
|
| Ho Mark |
Principal Accounting Officer |
– – – |
2021-03-02 |
4 |
D |
$62.15 |
$30,454 |
D/D |
(490) |
71,728 |
|
- |
|
| Kennedy Keith |
COO / CFO |
• – – |
2021-03-02 |
4 |
D |
$62.15 |
$359,413 |
D/D |
(5,783) |
116,858 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2021-03-02 |
4 |
D |
$62.15 |
$392,788 |
D/D |
(6,320) |
177,948 |
|
- |
|
524 Records found
|
|
Page 7 of 21 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.91 (4.33%) 
